Protein disulfide isomerase capture during thrombus formation in vivo depends on the presence of β3 integrins

Blood

Volumn 120, Issue 3, 2012, Pages 647-655

  Cho, Jaehyung ^a,b   Kennedy, Daniel R ^a,c   Lin, Lin ^a   Huang, Mingdong ^a   Merrill Skoloff, Glenn ^a   Furie, Barbara C ^a   Furie, Bruce ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c WESTERN NEW ENGLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; FIBRIN; PROTEIN DISULFIDE ISOMERASE; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTICLE; BLOOD VESSEL INJURY; BONE MARROW; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ANALYSIS; ENZYME BINDING; MALE; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE; THROMBOGENESIS;

EID: 84864125078     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-372532     Document Type: Article

References (35)

1. Wilkinson B, Gilbert HF. Protein disulfide isomerase. Biochim Biophys Acta. 2004;1699(1-2):35-44. (Pubitemid 38680792)
2. Munro S, Pelham HR. A C-terminal signal prevents secretion of luminal ER proteins. Cell. 1987;48(5):899-907.
3. Chen K, Lin Y, Detwiler TC. Protein disulfide isomerase activity is released by activated platelets. Blood. 1992;79(9):2226-2228.
4. Essex DW, Li M, Miller A, Feinman RD. Protein disulfide isomerase and sulfhydryl-dependent pathways in platelet activation. Biochemistry. 2001;40(20):6070-6075. (Pubitemid 32466310)
5. Essex DW, Chen K, Swiatkowska M. Localization of protein disulfide isomerase to the external surface of the platelet plasma membrane. Blood. 1995;86(6):2168-2173.
6. Jasuja R, Furie B, Furie BC. Endothelium-derived but not platelet-derived protein disulfide isomerase is required for thrombus formation in vivo. Blood. 2010;116(22):4665-4674.
7. Cho J, Furie BC, Coughlin SR, Furie B. A critical role for extracellular protein disulfide isomerase during thrombus formation in mice. J Clin Invest. 2008;118(3):1123-1131. (Pubitemid 351364619)
8. Reinhardt C, von Bruhl ML, Manukyan D, et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest. 2008; 118(3):1110-1122. (Pubitemid 351364618)
9. Atkinson BT, Jasuja R, Chen V, Nandivada P, Furie B, Furie BC. Laser-induced endothelial cell activation supports fibrin formation. Blood. 2010; 116(22):4675-4683.
10. Lahav J, Jurk K, Hess O, et al. Sustained integrin ligation involves extracellular free sulfhydryls and enzymatically catalyzed disulfide exchange. Blood. 2002;100(7):2472-2478.
11. Sun QH, Liu CY,Wang R, Paddock C, Newman PJ. Disruption of the long-range GPIIIa Cys(5)-Cys(435) disulfide bond results in the production of constitutively active GPIIb-IIIa (alphaIIbbeta3) integrin complexes. Blood. 2002;100(6):2094-2101. (Pubitemid 35001243)
12. Butta N, Arias-Salgado EG, Gonzalez-Manchon C, et al. Disruption of the beta3 663-687 disulfide bridge confers constitutive activity to beta3 integrins. Blood. 2003;102(7):2491-2497. (Pubitemid 37193587)
13. Mor-Cohen R, Rosenberg N, Landau M, Lahav J, Seligsohn U. Specific cysteines in beta3 are involved in disulfide bond exchange-dependent and -independent activation of alphaIIbbeta3. J Biol Chem. 2008;283(28):19235-19244.
14. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673-687. (Pubitemid 35283958)
15. Lawler J, Hynes RO. An integrin receptor on normal and thrombasthenic platelets that binds thrombospondin. Blood. 1989;74(6):2022-2027. (Pubitemid 19269104)
16. Swiatkowska M, Szymanski J, Padula G, Cierniewski CS. Interaction and functional association of protein disulfide isomerase with alphaV-beta3 integrin on endothelial cells. FEBS J. 2008;275(8):1813-1823. (Pubitemid 351464001)
17. Jordan PA, Stevens JM, Hubbard GP, et al. A role for the thiol isomerase protein ERP5 in platelet function. Blood. 2005;105(4):1500-1507. (Pubitemid 40223666)
18. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood. 1988;71(4):831-843.
19. Uzan G, Prenant M, Prandini MH, Martin F, Marguerie G. Tissue-specific expression of the platelet GPIIb gene. J Biol Chem. 1991;266(14):8932-8939.
20. Lam SC, Plow EF, D'Souza SE, Cheresh DA, Frelinger AL 3rd, Ginsberg MH. Isolation and characterization of a platelet membrane protein related to the vitronectin receptor. J Biol Chem. 1989;264(7):3742-3749. (Pubitemid 19072251)
21. Cheresh DA. Structural and biologic properties of integrin-mediated cell adhesion. Clin Lab Med. 1992;12(2):217-236.
22. Byzova TV, Rabbani R, D'Souza SE, Plow EF. Role of integrin alpha(v)beta3 in vascular biology. Thromb Haemost. 1998;80(5):726-734. (Pubitemid 28521714)
23. Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science. 1983;222(4628):1129-1132. (Pubitemid 14203781)
24. Gibson RM, Kansas GS, Tedder TF, Furie B, Furie BC. Lectin and epidermal growth factor domains of P-selectin at physiologic density are the recognition unit for leukocyte binding. Blood. 1995;85(1):151-158.
25. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. Beta3-integrin- deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999;103(2):229-238. (Pubitemid 29053141)
26. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med. 2002;8(10):1175-1181.
27. Smyth SS, Reis ED, Vaananen H, Zhang W, Coller BS. Variable protection of beta 3-integrin-deficient mice from thrombosis initiated by different mechanisms. Blood. 2001;98(4):1055-1062.
28. Vandendries ER, Hamilton JR, Coughlin SR, Furie B, Furie BC. PAR4 is required for maximal platelet accumulation but not fibrin generation after laser-induced vascular injury in an in vivo mouse model of thrombosis. Proc Natl Acad Sci U S A. 2007;104(1):288-292. (Pubitemid 46068024)
29. Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell. 1986;44(4):517-518.
30. Coller BS, Seligsohn U, Peretz H, Newman PJ. Glanzmann thrombasthenia: new insights from an historical perspective. Semin Hematol. 1994;31(4):301-311. (Pubitemid 24325182)
31. Castaldi PA, Larrieu MJ, Caen J. Availability of platelet factor 3 and activation of factor XII in thrombasthenia. Nature. 1965;207(995):422-424.
32. Weiss HJ, Lages B. Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity: a comparison with Scott Syndrome. Blood. 1997;89(5):1599-1611. (Pubitemid 27097453)
33. Caen J, Wu Q. Hageman factor, platelets and polyphosphates: early history and recent connection. J Thromb Haemost. 2010;8(8):1670-1674.
34. Müller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009;139(6):1143-1156.
35. Chen VM, Ahamed J, Versteeg HH, Berndt MC, Ruf W, Hogg PJ. Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry. 2006;45(39):12020-12028. (Pubitemid 44497827)